Evidence map›Paper›PMID 35013765›Full record

ArticleCancer immunology, immunotherapy : CII2022

Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.

Ryuhei Okada, Takuya Kato, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Daiki Fujimura, Shuhei Okuyama, Hideyuki Furumoto, Hiroshi Fukushima, Peter L Choyke and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ryuhei OkadaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Takuya KatoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Fuyuki InagakiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Hiroaki WakiyamaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Daiki FujimuraMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Shuhei OkuyamaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Hideyuki FurumotoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Hiroshi FukushimaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC 1088, 10 Center Drive, Bethesda, MD, 20892, USA. kobayash@mail.nih.gov.ORCID http://orcid.org/0000-0003-1019-4112
National Institutes of Health · US

Funding

Growth Factor Imaging and PhotoimmunotherapyZIABC010656 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2024
$31.6M
Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Intramural NIH HHS ZIA BC011513NCI NIH HHS ZIA BC011513
6 · The paper itself

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a cell-specific cancer therapy that uses an antibody-photoabsorber (IRDye700DX, IR700) conjugate (APC) and NIR light. Intravenously injected APC binds the target cells, and subsequent NIR light exposure induces immunogenic cell death only in targeted cells. Panitumumab and cetuximab are antibodies that target human epidermal growth factor receptor (hEGFR) and are suitable for NIR-PIT. In athymic nude mouse models, panitumumab-based NIR-PIT showed superior therapeutic efficacy compared to cetuximab-based NIR-PIT because of the longer half-life of panitumumab-IR700 (pan-IR700) compared with cetuximab-IR700 (cet-IR700). Two light exposures on two consecutive days have also been shown to induce superior effects compared to a single light exposure in the athymic nude mouse model. However, the optimal regimen has not been assessed in immunocompetent mice. In this study, we compared panitumumab and cetuximab in APCs for NIR-PIT, and single and double light exposures using a newly established hEGFR-expressing cancer cell line derived from immunocompetent C57BL/6 mice (mEERL-hEGFR cell line). Fluorescence imaging showed that the decline of pan-IR700 was slower than cet-IR700 confirming a longer clearance time. Among all the combinations tested, mice receiving pan-IR700 and double light exposure showed the greatest tumor growth inhibition. This group was also shown to activate CD8

Indexed as

ImmunotherapyPhotosensitizing AgentsAnimalsCell Line, TumorCetuximabErbB ReceptorsHumansMiceMice, Inbred C57BLMice, NudePanitumumabXenograft Model Antitumor AssaysCetuximabEGFR protein, humanErbB ReceptorsPanitumumabPhotosensitizing AgentsCetuximabEpidermal growth factor receptormEERLPanitumumabPhotoimmunotherapy

Identifiers

PMID35013765
PMCPMC9271517
OpenAlexW4206665107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.